Aethlon Medical, Inc.
AEMD Healthcare Medical Devices
Aethlon Medical, Inc.’s revenue for fiscal 2023 (year ended March 2023) was $574,200.00, up 95.2% from fiscal 2022. In the quarter to June 2026, EPS grew 90.5% and free cash flow fell 11.1%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow AEMD
Aethlon Medical, Inc. (AEMD) EV/Sales
As of 16 October 2026, Aethlon Medical, Inc. (AEMD) trades at a EV/Sales of −2.8×. Over the past ten years it has ranged from −46.0× (December 2022) to 458× (January 2015); the current reading is higher than 26% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −8.0× | — |
| FY2022 | 18.4× | 52.97% |
| FY2021 | 12.0× | — |
| FY2020 | −4.5× | — |
| FY2019 | 34.4× | 73.43% |
| FY2018 | 19.9× | (36.20%) |
| FY2017 | 31.1× | (9.60%) |
| FY2016 | 34.4× | (61.55%) |
| FY2015 | 89.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2023 | −7.9× | — |
| Mar 2022 | 18.4× | (33.77%) |
| Dec 2021 | 27.7× | (29.47%) |
| Sep 2021 | 39.3× | 1.50% |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AEMD Aethlon Medical, Inc. | −2.8× |
| TNON Tenon Medical, Inc. compare | −0.1× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| NMTC NeuroOne Medical Technologies Corporation compare | 0.7× |
| CTSO Cytosorbents Corporation compare | 0.7× |
| BMRA Biomerica, Inc. compare | 0.9× |
| BTCY Biotricity Inc. compare | 1.7× |
| PETV PetVivo Holdings, Inc. compare | 23.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)